NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies, today disclosed that positive phase 3 results for aglatimagene besadenovec (CAN-2409) in intermediate-to-high-risk localized prostate cancer will be presented at the 2025 ASCO Annual Meeting in Chicago. The pivotal trial met its primary endpoint with “statistically significant improvement in DFS (p=0.0155) with a 30% reduction (HR 0.7) in the risk for prostate cancer recurrence or death” in patients receiving CAN-2409 plus valacyclovir compared to placebo.

This advancement transforms treatment outcomes for the approximately 30% of intermediate-to-high-risk patients who experience disease recurrence following standard radiotherapy. The therapy induced “80.4% pathological complete responses in the two-year post-treatment biopsies compared to 63.6% observed in the control arm (p=0.0015)” while maintaining a favorable safety profile with only mild-to-moderate flu-like symptoms. According to CEO Paul Peter Tak, M.D., Ph.D., the company advances toward “submitting a Biologics License Application for CAN-2409 in the fourth quarter of 2026” to bring this “potentially transformative treatment to patients in need of better options.”

Read the full article on the Candel Therapeutics Website